Ashley Chan

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.

Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

NEO100 was given rare pediatric disease designation by the FDA for the treatment of patients with pediatric-type diffuse high-grade glioma.

A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.

Cilta-cel improved rates of MRD negativity and 30-month PFS vs SOC in patients with lenalidomide-refractory multiple myeloma with MRD negativity.

Tisotumab vedotin was granted approval by the EU for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

The addition of tumor treating fields to paclitaxel did not lead to a statistically significant overall survival improvement in platinum-resistant ovarian cancer.

Yufei Liu, MD, PhD, discusses current radiation strategies, including SBRT and IMRT, along with the benefits of radiation therapy in colorectal cancer.

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

Tanya Gupta, MD, details FDA-approved CDK4/6 inhibitors and considerations for selecting treatment in HR-positive, HER2-negative metastatic breast cancer.

Andreas M. Kaiser, MD, discusses strategies to reduce postoperative complications and determine surgical eligibility in patients with CRC.

Reshma Jagsi, MD, DPhil, highlights her journey to becoming a radiation oncologist and the nuances of intersectionality as a woman in oncology.

PEP-010 has been granted an orphan drug designation by the FDA for the treatment of patients with metastatic pancreatic cancer.

Tanya Gupta, MD, highlights the utility of adjuvant CDK4/6 and PARP inhibitors in patients with HR-positive, HER2-negative breast cancer.

Aditya Shreenivas, MD, MS, discusses the association between Claudin 18 and MUC1 biomarkers and ongoing targeted therapy challenges.

Andreas M. Kaiser, MD, discusses the differences between minimally invasive surgical approaches for colorectal cancer in community vs academic settings.

Patients with relapsed/refractory MCL who opted for elective treatment interruptions from venetoclax/ibrutinib experienced durable responses.

Palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole in patients with ER-positive advanced endometrial cancer.

Preclinical cytotoxicity was demonstrated with anti-CD38-CAR-gamma-delta T cells in multiple myeloma.

John M. Burke, MD, discusses identified challenges in the initiation of venetoclax in patients with CLL within a community-based setting.

Vepdegestrant improved PFS in ESR1-mutated, ER-positive, HER2-negative metastatic breast cancer, but PFS was not improved in the ITT population.

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.

Sewit Teckie, MD, discusses the advantages and disadvantages of a cfDNA blood-based assay compared with colonoscopy in diagnosing colorectal cancer.

The FDA granted RMAT designation to nogapendekin alfa inbakicept/CAR-NK for lymphopenia reversal in patients with advanced or metastatic pancreatic cancer.

Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.

The CHMP has recommended the approval of perioperative durvalumab plus neoadjuvant chemotherapy for patients with resectable NSCLC.